 19. Patient is receiving chronic treatment with systemic steroids or another immuno-suppressive agent at start of study treatment. Note: Topical applications e.g., rash, inhaled sprays e.g., obstructive airways diseases, eye drops or local injections e.g., intra-articular and the use of systemic steroids up to a prednisone equivalent of 10 mg daily are allowed. 